This bill seeks to improve the insulin safety net program in Minnesota by providing a clear definition of "covered insulin" and establishing a manufacturer registration fee. It amends various sections of the Minnesota Statutes to clarify eligibility criteria for individuals needing urgent access to insulin, outline the responsibilities of manufacturers, and define the roles of the Board of Pharmacy and MNsure in facilitating access. Key insertions include the definition of "covered insulin" as a drug prescribed for diabetes treatment and the requirement for manufacturers to offer patient assistance programs for eligible individuals. The bill also details the process for accessing urgent-need insulin, including the development of an application form by MNsure and the responsibilities of pharmacies in dispensing insulin.

Additionally, the legislation introduces penalties for manufacturers who do not comply with the program's requirements, including a tiered administrative penalty structure. It mandates the protection of privacy for data collected from individuals applying for assistance and requires annual reporting on the number of residents accessing urgent-need insulin. The bill also repeals a previous subdivision related to program satisfaction surveys, indicating a shift towards streamlining program administration rather than assessing satisfaction through surveys. Overall, the bill aims to enhance access to necessary diabetes treatment for Minnesota residents while ensuring accountability from manufacturers.

Statutes affected:
Introduction: 151.74, 13.381, 151.741